Apr 26, 2007 by Brian LawlerLilly Tries to Make Dogs HappyEli Lilly begins marketing a new drug that may revolutionize the pharmaceutical world.
Apr 25, 2007 by Brian LawlerWhere Is Elan Going?Drugmaker Elan announces first-quarter financial results.
Apr 25, 2007 by Brian LawlerNothing Wrong With NovartisNovartis releases first-quarter financial results
Apr 25, 2007 by Brian LawlerCVT Continues Its Spending SpreeCV Therapeutics releases first-quarter financial results.
Apr 25, 2007 by Brian LawlerExelixis Pushes AheadExelixis resumes development of one of its top compounds.
Apr 24, 2007 by Brian LawlerAtheroGenics Loses a PartnerAtheroGenics' drug-development partner bails.
Apr 24, 2007 by Brian LawlerGilead's Sales Are Galloping AheadGilead announces first-quarter financial results.
Apr 24, 2007 by Brian LawlerIs the Worst Over for QLT?QLT announces another dismal quarter of declining sales for its top compound.
Apr 24, 2007 by Brian LawlerAmgen On Sale?Biotech giant Amgen announces first-quarter financial results.
Apr 23, 2007 by Brian LawlerNeurochem Sets Low ExpectationsNeurochem announces an update on plans to release results from a clinical study.
Apr 23, 2007 by Brian LawlerTrimeris Isn't TumblingTrimeris announces first-quarter sales numbers for its HIV drug Fuzeon.
Apr 18, 2007 by Brian LawlerVertex's Billion-Dollar Drug?Vertex announces new clinical trial data for its top drug candidate.
Apr 17, 2007 by Brian LawlerNeurochem Must WaitThe FDA delays a regulatory decision on Neurochem's lead compound.
Apr 17, 2007 by Brian LawlerMerck Raises the Earnings RoofShares of Merck soar after it raises 2007 earnings guidance.
Apr 17, 2007 by Brian LawlerImClone Loses an IndicationImClone's lead drug fails in a clinical trial.
Apr 17, 2007 by Brian LawlerWill CVT Bring In the Dough?Investors are hoping for an increased rate of sales for CVT's top product.
Apr 13, 2007 by Brian LawlerGenentech Is Still HealthyGenentech announces its first-quarter financial results.
Apr 13, 2007 by Brian LawlerMedImmune Wants a MateMedImmune announces the hiring of investment bankers to look for a possible acquirer.
Apr 12, 2007 by Brian LawlerInterMune Roots for Its RivalsInterMune presents data from its HCV drug candidate.
